| To: rkrw who wrote (141) | 6/30/2006 11:34:05 AM | | From: DewDiligence_on_SI | | | | Copaxone accounted for nearly 30% of teva's sales in q1, how can it comprise just 15% of profits at branded margins?
You’re double counting (among other errors).
TEVA splits Copaxone 50/50 with SNY.
TEVA’s share of 1Q06 Copaxone sales was $165M, which was 9.8% of TEVA’s overall 1Q06 sales of $1.67B. |
| | Momenta Pharmaceuticals Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: DewDiligence_on_SI who wrote (140) | 6/30/2006 12:44:54 PM | | From: IRWIN JAMES FRANKEL | | | | >> Best I can tell Copaxone accounts for most if not all of their net income and it is off-patent.
>Do you consider 15% “most”?
Hardly.
Run rate Copaxone sales $1.3B
Overall GM 47% which dramatically understates the Copaxone margin by including the generics.
So assume the GM is 80%. Thus, gross profits from $1.3B is $1.04B.
That would account for most if not all of the net income.
BTW, what really is the NI of TEVA? Did you notice the writeoff of $1B in R&D in 1Q? What is the future income driver now that the pharma's are taking back the golden goose of "exclusivity"?
Bottom line, Copaxone is a very large part (perhaps even most or all) of the TEVA net income.
ij |
| | Momenta Pharmaceuticals Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: tuck | 7/24/2006 12:25:00 PM | | | | | | MNTA is up almost 13% this morning on no news I can find. Volume does not suggest that someone large knows something. I therefore think it's a retail bounce in a volatile stock. I own some stock and sold a bunch of puts, all of which are under water. The put selling strategy worked great until April. Anyhow, given the above, I just bought a few shorter term puts. MNTA is trying to push through its 50 day MAs on basically nothing but a market bounce. I think that'll be fairly strong resistance, and the next time the market gives up some ground, MNTA will be doing so as well.
stockcharts.com
Just my humble opinion, FWIW. I'd love to be wrong. If it gets through the 50 days, it's got some room to run. I'll take a small loss on my August puts and be very, very, happy.
Cheers, Tuck |
| | Momenta Pharmaceuticals Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: rkrw who wrote (148) | 7/25/2006 9:52:03 AM | | From: dr.praveen | | | | Momenta Pharmaceuticals and Sandoz Sign Exclusive Collaboration to Develop Complex Generics and Follow-On Versions of Biotechnology Drugs
Tuesday July 25, 9:45 am ET
Focus on developing four complex generic and follow-on biotechnology drugs, capitalize on Momenta's complex product characterization technology
Commitment of up to $263 million for four major products
CAMBRIDGE, Mass., July 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA - News), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced an exclusive collaboration with Sandoz, the generics business of Novartis, to develop four follow-on and complex generic versions of previously approved recombinant biotechnology and complex drugs.
As part of the collaboration, Sandoz will make an initial payment of $75 million to Momenta for the purchase of approximately 4.7 million shares at a price of $15.93 per share, a 30% premium to the trailing 30-day average. Momenta is also eligible to receive up to $188 million in additional payments if all milestones are achieved for the four product candidates.
The collaboration will include one late-stage compound from Momenta's pipeline and two late-stage compounds from Sandoz.
The collaboration also expands the companies' existing U.S. partnership on M-Enoxaparin, which was established in November 2003, to the European Union. M-Enoxaparin is a technology-enabled generic version of Lovenox®, a low molecular weight heparin indicated for use in treating deep vein thrombosis (DVT) and several cardiovascular conditions. In August 2005, an Abbreviated New Drug Application (ANDA) was submitted to the U.S. Food and Drug Administration seeking marketing approval for M-Enoxaparin.
The two companies will jointly develop, manufacture and commercialize all of these candidates, and share the profits from the sales of all products under separate profit share arrangements for each product, including an equal profit split specifically on the product candidate from Momenta's pipeline.
"Complex generics and follow-on proteins are one of the most rapidly evolving areas of product development in the pharmaceutical industry," said Alan Crane, CEO of Momenta. "With this partnership, we believe we will be well positioned to capitalize on this untapped potential and realize significant product value. Sandoz' decision to partner with Momenta across a spectrum of products highlights the broad potential of our analytic technology and the role that it can play in helping to set the standard for bringing well-characterized complex generic and follow-on protein products to market."
The product candidates in the collaboration will all leverage Momenta's characterization technology, which enables the detailed chemical sequencing and analysis of complex mixtures. Momenta's goal is to apply its technology to create generic and follow-on versions of complex drugs and biologics, which have been difficult to thoroughly characterize. The collaboration will also leverage the global capabilities and infrastructure of Sandoz for developing, manufacturing, and marketing complex drugs.
The purchase of Momenta shares and the collaboration are subject to customary regulatory reviews and approvals, including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act.
Conference Call Information
Momenta will host a conference call on July 25, 2006 at 10:30 am EDT to discuss this collaboration. To access the call, please dial 800-435-1261 (domestic) or 617-614-4076 (international) prior to the scheduled conference call time and provide the access code 91534008. A replay of the call will be available approximately two hours after the call and will be accessible through July 31, 2006. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and provide the access code 84803954.
A live audio webcast of the call will be available on the "Investors" section of the Company's website, momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call and will be available through August 25, 2006.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed characterization and engineering of complex sugars. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, develop improved versions of existing drugs, and discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology- enabled generic version of Lovenox®. An ANDA was filed for M-Enoxaparin in August 2005 in collaboration with Sandoz, the generics division of Novartis AG. Momenta has multiple technology-enabled generic products in its pipeline. Momenta's first improved drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. The Company is also developing novel drug candidates through its discovery effort focused on understanding novel sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at momentapharma.com, which does not form a part of this press release |
| | Momenta Pharmaceuticals Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| |
